Table 2.
Incident cancer diagnoses
| STEMI patients | Rotterdam study | |
|---|---|---|
| n = 1809 | n = 10,052 | |
| All incident cancers | 115 | 677 |
| Cancer subtypes | ||
| Upper gastrointestinal | 10 (8.7) | 30 (4.4) |
| Hepatobiliary and panreatic | 2 (1.7) | 27 (4.0) |
| Colorectal | 15 (13.0) | 118 (17.4) |
| Breast | 7 (6.1) | 107 (15.8) |
| Prostate | 18 (15.7) | 111 (16.4) |
| Genital | 1 (0.9) | 24 (3.5) |
| Urologic | 11 (9.6) | 63 (9.3) |
| Otolaryngol | 3 (2.6) | 20 (3.0) |
| Lung | 23 (20.0) | 81 (12.0) |
| Melanoma | 9 (7.8) | 26 (3.8) |
| Hematologic | 10 (8.7) | 37 (5.5) |
| Other/unknown primary origin | 6 (5.2) | 33 (4.9) |
| Metastases at cancer diagnosis | 21 (18.3) | 97 (14.3) |
| Incident cancers by follow-up time strata | ||
| 0–3 Months | 15 (13.0) | 22 (3.2) |
| 3–6 Months | 11 (9.6) | 32 (4.7) |
| 6–12 Months | 16 (13.9) | 66 (9.7) |
| 12–24 Months | 26 (22.6) | 158 (23.3) |
| 24–60 Months | 47 (40.9) | 399 (58.9) |
Values are counts (percentages among total number of cancer cases)